Genetic Technologies is a leading-edge molecular testing business with over 20 years experience globally. The Company specialises in providing an extensive portfolio of genetic tests, including those addressing various aspects of cancer development, progression and management.
Genetic Technologies is the only genetic testing company with testing options directed at both familial and non-familial breast cancer. We provide accurate and rapid turnaround times with the choice of express testing options. Genetic Technologies’ molecular tests provide personalised and actionable diagnostic results to patients and clinicians enabling them to make better informed choices and access to intervention strategies.
Listed on the ASX (GTG) and NASDAQ (GENE), Genetic Technologies has created a successful multi-faceted genetic testing business together with expertise in the intellectual property field. The Company partners with world leading suppliers, clinical researchers and academic collaborators.
Following the acquisition of BREVAGen™, a proprietary breast cancer risk assessment test, Genetic Technologies has established operations in the US (Phenogen Sciences, Inc., a US division of Australia-based Genetic Technologies Limited) enabling us to offer this exciting test in all 50 states.
Gallery View 4: (Full Sto, MACD, Aroon8)